Cancer immunotherapy has been predominantly focused on biologically based intervention strategies. However, recent advances in the understanding of tumour-host interactions at the molecular level have revealed targets that might be amenable to intervention with small-molecule inhibitors. In particular, key effectors of tumoral immune escape have been identified that contribute to a dominant toleragenic state that is suspected of limiting the successful implementation of treatment strategies that rely on boosting immune function. Within the context of the pathophysiology of cancer-associated immune tolerance, this Review delineates potential molecular targets for therapeutic intervention and the progress that has been made in developing small-molecule inhibitors. © 2006 Nature Publishing Group.
CITATION STYLE
Muller, A. J., & Scherle, P. A. (2006, August). Targeting the mechanisms of tumoral immune tolerance with small-molecule inhibitors. Nature Reviews Cancer. https://doi.org/10.1038/nrc1929
Mendeley helps you to discover research relevant for your work.